Last reviewed · How we verify

NCT05339139: SARCA

SAfety of Regional Citrate Anticoagulation (SARCA Study)

Recruiting now Phase 3 Last updated 24 April 2025
What this trial tests

Phase 3 trial testing Dialysis in Acute Kidney Injury in 50 participants. Currently enrolling.

Timeline
17 October 2023
Primary endpoint
30 April 2025
31 July 2025

Quick facts

Lead sponsorFresenius Medical Care North America
PhasePhase 3
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment50
Start date17 October 2023
Primary completion30 April 2025
Estimated completion31 July 2025
Sites10 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Fresenius Medical Care North America — full company profile →

Who can join

18 and older, any sex, with Acute Kidney Injury or ESRD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an Open-label, Prospective, Multicenter Study to Assess the SAfety of Regional Citrate Anticoagulation Delivered by the multiFiltratePRO system in Adult Patients Requiring Continuous Renal Replacement Therapy (SARCA Study).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Dialysis

Trials testing the same drug.

Other recruiting trials for Acute Kidney Injury

Currently open trials in the same condition.

Other Fresenius Medical Care North America trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05339139.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing